CardieX (ASX:CDX) Research & Development : A$3.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is CardieX Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. CardieX's Research & Development for the six months ended in Dec. 2023 was A$1.31 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$3.19 Mil.

CardieX Research & Development Historical Data

The historical data trend for CardieX's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardieX Research & Development Chart

CardieX Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Research & Development

Get a 7-Day Free Trial

0.63

0.92

2.38

3.91

CardieX Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															-	-	2.03	1.88	1.31

CardieX Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.19 Mil.

CardieX (ASX:CDX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CardieX Research & Development Related Terms

Thank you for viewing the detailed overview of CardieX's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

CardieX (ASX:CDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000

Website

https://www.cardiex.com

CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.

CardieX (ASX:CDX) Headlines

No Headlines